For example, the reported presence in CSF of short endogenous tau peptides containing pT181 that are not increased in Alzheimer’s disease [48], may decrease the performance of the PRM assay for this peptide, compared to pT181 immunoassays that require a longer tau fragment for detection. This evidence concerns the gene MAPT and Alzheimer disease.